{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:31:25Z","timestamp":1707525085612},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,4]]},"DOI":"10.7759\/cureus.37126","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T19:49:39Z","timestamp":1680637779000},"source":"Crossref","is-referenced-by-count":0,"title":["Achieving the Sustained Virologic Response With a Short-Course Treatment of Sofosbuvir\/Velpatasvir"],"prefix":"10.7759","author":[{"given":"Simon P","family":"Abi-Saleh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Ghazal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Urtasun Sotil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo QL","year":"1989","unstructured":"Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989, 244:359-62. 10.1126\/science.2523562","journal-title":"Science"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31003","article-title":"Short-duration pan-genotypic therapy with glecaprevir\/pibrentasvir for 6 weeks among people with recent hepatitis C viral infection","volume":"72","author":"Martinello M","year":"2020","unstructured":"Martinello M, Orkin C, Cooke G, et al.. Short-duration pan-genotypic therapy with glecaprevir\/pibrentasvir for 6 weeks among people with recent hepatitis C viral infection. Hepatology. 2020, 72:7-18. 10.1002\/hep.31003","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30408-X","article-title":"Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study","volume":"17","author":"Deterding K","year":"2017","unstructured":"Deterding K, Spinner CD, Schott E, et al.. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis. 2017, 17:215-22. 10.1016\/S1473-3099(16)30408-X","journal-title":"Lancet Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12917","article-title":"Shortened therapy of eight weeks with paritaprevir\/ritonavir\/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection","volume":"25","author":"Martinello M","year":"2018","unstructured":"Martinello M, Bhagani S, Gane E, et al.. Shortened therapy of eight weeks with paritaprevir\/ritonavir\/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection. J Viral Hepat. 2018, 25:1180-8. 10.1111\/jvh.12917","journal-title":"J Viral Hepat"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2939","article-title":"Underascertainment of acute hepatitis C virus infections in the U.S. surveillance system: a case series and chart review","volume":"163","author":"Onofrey S","year":"2015","unstructured":"Onofrey S, Aneja J, Haney GA, et al.. Underascertainment of acute hepatitis C virus infections in the U.S. surveillance system: a case series and chart review. Ann Intern Med. 2015, 163:254-61. 10.7326\/M14-2939","journal-title":"Ann Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2020.101596","article-title":"Epidemiology of hepatitis C virus infection","volume":"45","author":"Roudot-Thoraval F","year":"2021","unstructured":"Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. Clin Res Hepatol Gastroenterol. 2021, 45:101596. 10.1016\/j.clinre.2020.101596","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4050","article-title":"Novel therapies for hepatitis C - one pill fits all?","volume":"12","author":"Manns MP","year":"2013","unstructured":"Manns MP, von Hahn T. Novel therapies for hepatitis C - one pill fits all?. Nat Rev Drug Discov. 2013, 12:595-610. 10.1038\/nrd4050","journal-title":"Nat Rev Drug Discov"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld JJ","year":"2015","unstructured":"Feld JJ, Jacobson IM, H\u00e9zode C, et al.. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015, 373:2599-607. 10.1056\/NEJMoa1512610","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14537","article-title":"Global real-world evidence of sofosbuvir\/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts","volume":"40","author":"Mangia A","year":"2020","unstructured":"Mangia A, Milligan S, Khalili M, et al.. Global real-world evidence of sofosbuvir\/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. Liver Int. 2020, 40:1841-52. 10.1111\/liv.14537","journal-title":"Liver Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry MP","year":"2015","unstructured":"Curry MP, O'Leary JG, Bzowej N, et al.. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015, 373:2618-28. 10.1056\/NEJMoa1512614","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy913","article-title":"Ledipasvir\/sofosbuvir for 8 weeks to treat acute hepatitis C virus infections in men with human immunodeficiency virus infections: sofosbuvir-containing regimens without interferon for treatment of acute HCV in HIV-1 infected individuals","volume":"69","author":"Naggie S","year":"2019","unstructured":"Naggie S, Fierer DS, Hughes MD, et al.. Ledipasvir\/sofosbuvir for 8 weeks to treat acute hepatitis C virus infections in men with human immunodeficiency virus infections: sofosbuvir-containing regimens without interferon for treatment of acute HCV in HIV-1 infected individuals. Clin Infect Dis. 2019, 69:514-22. 10.1093\/cid\/ciy913","journal-title":"Clin Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.04.056","article-title":"Sofosbuvir\/velpatasvir for 12 vs. 6 weeks for the treatment of\u00a0recently acquired hepatitis C infection","volume":"75","author":"Matthews GV","year":"2021","unstructured":"Matthews GV, Bhagani S, Van der Valk M, et al.. Sofosbuvir\/velpatasvir for 12 vs. 6 weeks for the treatment of\u00a0recently acquired hepatitis C infection. J Hepatol. 2021, 75:829-39. 10.1016\/j.jhep.2021.04.056","journal-title":"J Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/147342-achieving-the-sustained-virologic-response-with-a-short-course-treatment-of-sofosbuvirvelpatasvir","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:57:40Z","timestamp":1707508660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/147342-achieving-the-sustained-virologic-response-with-a-short-course-treatment-of-sofosbuvirvelpatasvir"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.37126","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,4]]}}}